Which has higher valuation & earnings, AVLN or CLLS?

Avalyn Pharma has higher earnings, but lower revenue than Cellectis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Avalyn Pharma N/A N/A N/A N/A N/A Cellectis $79.59M 3.66 -$67.59M -$0.67 N/A

Does the media favor AVLN or CLLS?

In the previous week, Avalyn Pharma had 2 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Avalyn Pharma and 1 mentions for Cellectis. Avalyn Pharma's average media sentiment score of 0.00 equaled Cellectis'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalyn Pharma 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CLLS or IMTX?

Cellectis has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectis $79.59M 3.66 -$67.59M -$0.67 N/A Immatics $54.60M 24.38 -$222.26M -$1.99 N/A

Is CLLS or IMTX more profitable?

Cellectis has a net margin of -89.51% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -89.51% -80.66% -20.51% Immatics -572.35% -47.36% -39.35%

Do analysts recommend CALT or CLLS?

Cellectis has a consensus price target of $7.00, suggesting a potential upside of 141.38%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cellectis 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Is XERS or CLLS more profitable?

Xeris Biopharma has a net margin of 3.81% compared to Cellectis' net margin of -89.51%. Xeris Biopharma's return on equity of 735.00% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Xeris Biopharma 3.81% 735.00% 3.24% Cellectis -89.51% -80.66% -20.51%

Does the media prefer XERS or CLLS?

In the previous week, Xeris Biopharma had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for Xeris Biopharma and 1 mentions for Cellectis. Xeris Biopharma's average media sentiment score of 1.53 beat Cellectis' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cellectis (CLLS) Competitors

$2.90 +0.08 (+2.84%)

As of 04:00 PM Eastern

Compare

CLLS vs. AVLN, DMRA, IMTX, CALT, and XERS

Should you buy Cellectis stock or one of its competitors? MarketBeat compares Cellectis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectis include Avalyn Pharma (AVLN), Damora Therapeutics, Inc. Common Stock (DMRA), Immatics (IMTX), Calliditas Therapeutics AB (publ) (CALT), and Xeris Biopharma (XERS). These companies are all part of the "pharmaceutical products" industry.

How does Cellectis compare to Avalyn Pharma?

Avalyn Pharma (NASDAQ:AVLN) and Cellectis (NASDAQ:CLLS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

In the previous week, Avalyn Pharma had 2 more articles in the media than Cellectis. MarketBeat recorded 3 mentions for Avalyn Pharma and 1 mentions for Cellectis. Avalyn Pharma's average media sentiment score of 0.00 equaled Cellectis'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalyn Pharma	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Avalyn Pharma presently has a consensus price target of $59.00, indicating a potential upside of 82.72%. Cellectis has a consensus price target of $7.00, indicating a potential upside of 141.38%. Given Cellectis' higher probable upside, analysts plainly believe Cellectis is more favorable than Avalyn Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalyn Pharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.20
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Avalyn Pharma has higher earnings, but lower revenue than Cellectis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalyn Pharma	N/A	N/A	N/A	N/A	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Avalyn Pharma has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Avalyn Pharma's return on equity of 0.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalyn Pharma	N/A	N/A	N/A
Cellectis	-89.51%	-80.66%	-20.51%

Summary

Avalyn Pharma beats Cellectis on 6 of the 11 factors compared between the two stocks.

How does Cellectis compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market.

Cellectis has higher revenue and earnings than Damora Therapeutics, Inc. Common Stock. Cellectis is trading at a lower price-to-earnings ratio than Damora Therapeutics, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

Damora Therapeutics, Inc. Common Stock has a net margin of 0.00% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Cellectis	-89.51%	-80.66%	-20.51%

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Damora Therapeutics, Inc. Common Stock presently has a consensus price target of $42.43, indicating a potential upside of 84.95%. Cellectis has a consensus price target of $7.00, indicating a potential upside of 141.38%. Given Cellectis' higher probable upside, analysts clearly believe Cellectis is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Cellectis had 1 more articles in the media than Damora Therapeutics, Inc. Common Stock. MarketBeat recorded 1 mentions for Cellectis and 0 mentions for Damora Therapeutics, Inc. Common Stock. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.00 equaled Cellectis'average media sentiment score.

Company	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	Neutral
Cellectis	Neutral

Summary

Cellectis beats Damora Therapeutics, Inc. Common Stock on 10 of the 15 factors compared between the two stocks.

How does Cellectis compare to Immatics?

Cellectis (NASDAQ:CLLS) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations, valuation and media sentiment.

Cellectis has a net margin of -89.51% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-89.51%	-80.66%	-20.51%
Immatics	-572.35%	-47.36%	-39.35%

Cellectis has a beta of 2.86, indicating that its stock price is 186% more volatile than the broader market. Comparatively, Immatics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Cellectis presently has a consensus target price of $7.00, indicating a potential upside of 141.38%. Immatics has a consensus target price of $20.80, indicating a potential upside of 109.47%. Given Cellectis' stronger consensus rating and higher probable upside, equities analysts plainly believe Cellectis is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

In the previous week, Cellectis had 1 more articles in the media than Immatics. MarketBeat recorded 1 mentions for Cellectis and 0 mentions for Immatics. Immatics' average media sentiment score of 1.27 beat Cellectis' score of 0.00 indicating that Immatics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cellectis	Neutral
Immatics	Positive

63.9% of Cellectis shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cellectis has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A
Immatics	$54.60M	24.38	-$222.26M	-$1.99	N/A

Summary

Cellectis beats Immatics on 12 of the 17 factors compared between the two stocks.

How does Cellectis compare to Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends.

Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, suggesting that its share price is 186% more volatile than the broader market.

In the previous week, Cellectis had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Cellectis and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 equaled Cellectis'average media sentiment score.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Cellectis	Neutral

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 16.4% of Cellectis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Cellectis. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

Calliditas Therapeutics AB (publ) has a net margin of -30.18% compared to Cellectis' net margin of -89.51%. Cellectis' return on equity of -80.66% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Cellectis	-89.51%	-80.66%	-20.51%

Cellectis has a consensus price target of $7.00, suggesting a potential upside of 141.38%. Given Cellectis' stronger consensus rating and higher probable upside, analysts plainly believe Cellectis is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Cellectis beats Calliditas Therapeutics AB (publ) on 13 of the 16 factors compared between the two stocks.

How does Cellectis compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 63.9% of Cellectis shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 16.4% of Cellectis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Xeris Biopharma has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Cellectis has a beta of 2.86, suggesting that its stock price is 186% more volatile than the broader market.

Xeris Biopharma has a net margin of 3.81% compared to Cellectis' net margin of -89.51%. Xeris Biopharma's return on equity of 735.00% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Cellectis	-89.51%	-80.66%	-20.51%

In the previous week, Xeris Biopharma had 1 more articles in the media than Cellectis. MarketBeat recorded 2 mentions for Xeris Biopharma and 1 mentions for Cellectis. Xeris Biopharma's average media sentiment score of 1.53 beat Cellectis' score of 0.00 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Xeris Biopharma currently has a consensus target price of $10.80, suggesting a potential upside of 50.00%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 141.38%. Given Cellectis' stronger consensus rating and higher possible upside, analysts plainly believe Cellectis is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Xeris Biopharma has higher revenue and earnings than Cellectis. Cellectis is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	4.26	$550K	$0.06	120.00
Cellectis	$79.59M	3.66	-$67.59M	-$0.67	N/A

Summary

Xeris Biopharma beats Cellectis on 10 of the 16 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$282.96M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	-4.33	19.75	24.92	23.98
Price / Sales	3.66	330.11	529.01	109.54
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	3.82	8.29	10.79	6.50
Net Income	-$67.59M	$23.85M	$3.56B	$336.88M
7 Day Performance	-4.92%	5.21%	1.67%	-0.22%
1 Month Performance	-17.14%	2.19%	0.43%	0.77%
1 Year Performance	101.39%	60.99%	32.84%	31.57%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	1.955 of 5 stars	$2.90 +2.8%	$7.00 +141.4%	+91.8%	$282.96M	$79.59M	N/A	290	News Coverage
AVLN Avalyn Pharma	4.6721 of 5 stars	$28.13 -2.2%	$59.00 +109.7%	N/A	$1.25B	N/A	N/A	51	News Coverage
DMRA Damora Therapeutics, Inc. Common Stock	2.0207 of 5 stars	$20.15 +0.4%	$42.43 +110.6%	+620.4%	$1.24B	N/A	N/A	40
IMTX Immatics	3.1654 of 5 stars	$9.16 -2.9%	$20.80 +127.1%	+74.3%	$1.23B	$54.60M	N/A	260	Positive News Gap Up
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. AVLN, DMRA, IMTX, CALT, and XERS

How does Cellectis compare to Avalyn Pharma?

Summary

How does Cellectis compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Cellectis compare to Immatics?

Summary

How does Cellectis compare to Calliditas Therapeutics AB (publ)?

Summary

How does Cellectis compare to Xeris Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. AVLN, DMRA, IMTX, CALT, and XERS

How does Cellectis compare to Avalyn Pharma?

Does the media favor AVLN or CLLS?

Do analysts recommend AVLN or CLLS?

Which has higher valuation & earnings, AVLN or CLLS?

Do insiders & institutionals believe in AVLN or CLLS?

Is AVLN or CLLS more profitable?

Summary

How does Cellectis compare to Damora Therapeutics, Inc. Common Stock?

Which has more risk & volatility, DMRA or CLLS?

Which has higher earnings & valuation, DMRA or CLLS?

Is DMRA or CLLS more profitable?

Do institutionals & insiders have more ownership in DMRA or CLLS?

Do analysts prefer DMRA or CLLS?

Does the media prefer DMRA or CLLS?

Summary

How does Cellectis compare to Immatics?

Is CLLS or IMTX more profitable?

Which has more risk & volatility, CLLS or IMTX?

Do analysts recommend CLLS or IMTX?

Does the media favor CLLS or IMTX?

Do insiders and institutionals believe in CLLS or IMTX?

Which has stronger earnings and valuation, CLLS or IMTX?

Summary

How does Cellectis compare to Calliditas Therapeutics AB (publ)?

Which has more risk and volatility, CALT or CLLS?

Does the media prefer CALT or CLLS?

Do insiders & institutionals hold more shares of CALT or CLLS?

Which has preferable earnings and valuation, CALT or CLLS?

Is CALT or CLLS more profitable?

Do analysts recommend CALT or CLLS?

Summary

How does Cellectis compare to Xeris Biopharma?

Do institutionals and insiders hold more shares of XERS or CLLS?

Which has more volatility and risk, XERS or CLLS?

Is XERS or CLLS more profitable?

Does the media prefer XERS or CLLS?

Do analysts recommend XERS or CLLS?

Which has stronger earnings & valuation, XERS or CLLS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools